Rapid decrease of wild-type hepatitis C virus on telaprevir treatment
| Autor: | John C. R. Randle, Avidan U. Neumann, Brian Hare, Hendrik W. Reesink, Paul R. Caron, Eva Herrmann, Bambang S. Adiwijaya, Stefan Zeuzem |
|---|---|
| Přispěvatelé: | Gastroenterology and Hepatology |
| Rok vydání: | 2008 |
| Předmět: |
Pharmacology
biology business.industry Hepacivirus Hepatitis C virus Hepatitis C biology.organism_classification medicine.disease_cause medicine.disease Virology Virus Telaprevir Flaviviridae Infectious Diseases medicine Pharmacology (medical) Protease inhibitor (pharmacology) Viral disease business medicine.drug |
| Zdroj: | Antiviral therapy, 14(4), 591-595. International Medical Press Ltd |
| ISSN: | 2040-2058 1359-6535 |
| DOI: | 10.1177/135965350901400402 |
| Popis: | Background Telaprevir (TVR) is a hepatitis C virus (HCV) NS3.4A protease inhibitor that has exhibited antiviral activity in patients with HCV genotype 1 infection. The viral dynamics in patients dosed with TVR were compared with those reported for patients treated with interferon (IFN). Methods The dynamics of wild-type HCV genotype 1 in patients dosed with TVR monotherapy ( n=36) and TVR plus pegylated interferon (PEG-IFN)-α2a ( n=8) were quantified using a biphasic viral dynamic model. Results Patients dosed with either TVR monotherapy or TVR plus PEG-IFN-α2a had median first and second phase decreases of 12 per day and 1.1 per day, respectively. The second phase decrease was approximately 10-fold higher than reported values for IFN-based treatments ( P10. In patients dosed with TVR mono-therapy, increased TVR dosage of the same schedule was related to better blockage. Conclusions These results suggested that TVR-based regimens for chronic HCV infection will lead to an early and more rapid viral decrease that could potentially result in higher sustained viral response rates as well as offer the potential for a reduced duration of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|